Plenacor

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Plenacor

Quick Facts

Property Description
Active ingredient Atenolol
Form Tablets
Pharmacological class Beta blocker (Cardioselective)
General Purpose Cardioprotection / Heart Workload Mitigation
Origin Synthetic

What Type of Medicine is Plenacor? (Identity and Classification)

Plenacor is a prescription-only medicine whose active component is Atenolol, classified as a beta-adrenergic blocking agent. It is a synthetic compound specifically designated as a selective beta1 adrenoceptor antagonist.

The fundamental identity of Plenacor centers on its pharmacological classification as a Beta blocker, a class of agents that modulate the heart's response to hormonal stimuli. Unlike older, non-selective alternatives, the use of Atenolol confers cardioselectivity at typical therapeutic levels, meaning the drug preferentially targets the beta1 receptors found mainly in the cardiac muscle. Atenolol's established history has been clinically recognized for its role in cardiovascular care across adult patient groups, supported by decades of pharmacological studies.

Composition and Dosage Form of Plenacor

The preparation is formulated as a single-ingredient product, available predominantly in the physical form of solid Tablets intended for oral administration.

The composition relies exclusively on the active substance Atenolol, combined with the necessary pharmaceutical excipients required to create the stable, solid dosage form suitable for ingestion. Atenolol is included on the World Health Organization's (WHO) List of Essential Medicines, which highlights its recognition as a critical and foundational medicine. The formulation as a single-ingredient product is characteristic of many foundational cardiovascular therapies.

General Purpose and Therapeutic Action

The general purpose of Plenacor is to provide cardioprotective benefits by reducing the overall workload placed upon the heart muscle. This occurs through selective beta1-receptor blockade, which moderates the heart's rhythm and the force of its contractions.

This fundamental action reduces the effects of circulating stress hormones on the cardiac system, resulting in Heart Workload Mitigation. By decreasing the heart rate and contraction strength, Plenacor reduces the oxygen demand of the heart, thereby supporting overall cardiac function. Its role is typically recognized in scenarios requiring long-term regulation of heart activity, establishing its essential therapeutic position in the general management of cardiovascular conditions.

Regulatory References

  1. MedlinePlus: Atenolol

What side effects are possible with Plenacor?

Possible Side Effects and Safety Information

The following information summarizes the officially documented adverse reactions and safety characteristics of Plenacor (Atenolol), based strictly on government regulatory documents. The potential effects are classified by the physiological system affected and their frequency of occurrence.

Frequency-Classified Adverse Reactions

Adverse reactions are categorized using standard regulatory terminology:

  • Common (may affect up to 1 in 10 patients): Fatigue, bradycardia (slowed heart rate), coldness in the extremities, and general gastrointestinal disturbances.
  • Uncommon (may affect up to 1 in 100 patients): Sleep disturbances and temporary elevations of liver transaminase levels.
  • Rare (may affect up to 1 in 1,000 patients): Deterioration of heart failure, postural hypotension, various mood changes, confusion, bronchospasm, and hepatic toxicity.

Documented System-Specific Safety Concerns

The official label lists effects across several system-organ classes, including cardiac disorders, nervous system disorders (dizziness, headache), psychiatric disorders (nightmares, hallucinations), and skin and subcutaneous tissue disorders (rashes, alopecia).

Population-Specific and Time-Related Safety Constraints

Safety statements highlight specific situations for regulatory consideration:

  • Renal Impairment: Dosage adjustment is mandated in individuals with significantly reduced kidney function to prevent drug accumulation.
  • Masking Symptoms: Plenacor may mask the physical signs of hypoglycemia in diabetic patients and the cardiovascular signs of thyrotoxicosis.
  • Abrupt Cessation Risk: Sudden withdrawal, particularly in patients with ischemic heart disease, carries the official risk of increased frequency or severity of angina attacks or deterioration of the cardiac state.

Serious reactions documented as rare or unknown frequency include precipitation of heart block, lupus-like syndrome, and severe hypersensitivity reactions.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information for Plenacor (Atenolol) emphasizes that an overdose may be associated with severe, life-threatening physiological disturbances, requiring immediate, specialized medical intervention.

Documented Overdose Presentations

Physiological System Documented Manifestations
Cardiovascular Profound bradycardia (severely slowed heart rate), severe hypotension (critically low blood pressure), acute cardiac failure.
Respiratory Bronchospasm (airway constriction), wheezing, or difficulty breathing.
Metabolic Hypoglycemia (dangerously low blood sugar).
Central Nervous System Lethargy, coma, or seizure activity.

Required Emergency Actions

When immediate medical help is required: Any suspected overdose must be managed immediately in an intensive care setting; call emergency services without delay.

Emergency-response statements (as written in official documents):

  • Measures to limit absorption, such as the administration of activated charcoal or gastric lavage, may be considered if ingestion was recent.
  • Treatment must be symptomatic and supportive, focused on stabilizing vital signs and managing specific toxic effects.
  • Pharmacologic interventions are required to counteract cardiovascular depression (e.g., Atropine for bradycardia, vasopressors for hypotension, Glucagon for cardiac failure).
  • The drug can be removed from the general circulation by haemodialysis due to its low protein binding.

Population-specific notes: Patients with severe impairment of renal function require specific monitoring and adjustment of management due to the drug's primary elimination via the kidneys.

Therapeutic Uses of Plenacor

What Plenacor Treats: Main Uses and Benefits

Plenacor is commonly used in situations involving certain distressing cardiovascular symptoms, with the goal of providing supportive benefits that help ease the overall symptom load. Its use includes the management of chronic high blood pressure, irregular heartbeats, and chest pain related to angina.

The medication plays a role in managing conditions characterized by periods of heightened symptoms, including sustained systemic hypertension, chronic Angina Pectoris, and various cardiac overactivity issues like palpitations. It is also considered relevant for long-term supportive management following a myocardial infarction and may assist with the prophylactic management of recurrent, disabling vascular headaches.


Quick Fact: Relief for Symptoms Related to Physical Discomfort

Symptom Domain General Benefit
Cardiac Overactivity (Palpitations, Rapid Heart Rate) Helps maintain a sense of stability when symptoms are more noticeable.
Chest Discomfort (Angina Pectoris) Supports the patient during difficult episodes by easing distress.
Systemic Strain (Hypertension) Assists with maintaining functional stability.

In clinical scenarios where additional symptomatic support is needed, Plenacor helps address symptom clusters that may become intense or disruptive. The medication is utilized across conditions presenting with acute episodes, providing supportive relief when symptoms interfere with routine activities and contributing to improved comfort during symptomatic periods.

Eligibility and Restrictions for Use

Who Can and Cannot Use Plenacor?

The eligibility to use Plenacor (atenolol) is determined by strict rules outlined in official regulatory documents, such as FDA Prescribing Information and the European Summary of Product Characteristics (SmPC).

Plenacor is approved for use in Adults for its official indications, but its use is strictly excluded or limited in several specific populations and conditions.

Eligibility Status Key Restrictions (Official Labeling)
Absolute Contraindications Cardiogenic Shock, Second- or Third-Degree Heart Block, Severe Sinus Bradycardia (typically <50 bpm), Overt Cardiac Failure, Metabolic Acidosis, and Untreated Pheochromocytoma.
Conditional Use Patients with Impaired Renal Function must receive a dose adjustment, as the drug is primarily kidney-excreted. Caution is required in patients with First-Degree Heart Block or severe conditions like asthma or COPD.
Not Recommended/Not Established Use is not recommended in children and adolescents (under 18) as safety and effectiveness have not been established. The drug is generally restricted during pregnancy and lactation due to potential risks to the fetus and neonate.

Older adults require caution due to the likelihood of reduced renal function. Furthermore, the label advises caution in conditions like diabetes and thyrotoxicosis, as Plenacor may mask critical signs of hypoglycemia or thyroid overactivity. The official eligibility profile strictly prohibits use in specific severe, unstable cardiac and metabolic states to mitigate risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Plenacor (Atenolol) is involved in various officially documented interactions, predominantly through pharmacodynamic reinforcement and altered exposure, as defined in regulatory labeling.

Official Interaction Statements

Co-administration with Calcium Channel Blockers (e.g., Verapamil, Diltiazem, Nifedipine) carries a high risk of additive effects, potentially leading to severe bradycardia and hypotension. A mandatory 48-hour separation is required when administering intravenous Verapamil or Diltiazem near the time of Plenacor discontinuation.

Interactions with Class I Anti-Arrhythmic Drugs (e.g., Disopyramide, Amiodarone) may potentiate cardiotoxicity, including negative inotropic effects. Additionally, co-use with Cardiac Glycosides (e.g., Digoxin) may increase auriculo-ventricular conduction time.

Exposure and Regulatory Constraints

Pharmacodynamic interactions exist with Prostaglandin Synthetase Inhibiting Drugs (NSAIDs), which may reduce Plenacor's antihypertensive effect. Plenacor can also intensify the effects of antidiabetic drugs and mask the warning sign of hypoglycemia (tachycardia).

Timing restrictions apply to Clonidine, which must only be withdrawn several days after discontinuing Plenacor to prevent rebound hypertension. Reduced kidney function (Impaired Renal Function) decreases clearance, leading to increased systemic exposure. Substances like Orange Juice and Multivitamin with Minerals are documented to moderately reduce Plenacor's absorption and bioavailability.

Mechanism of Action

Plenacor's mechanism of action involves targeted beta-adrenergic receptor antagonism to influence cardiovascular and systemic responses.


Cardioselective beta1-Receptor Blockade

Plenacor functions as a beta1-selective adrenergic antagonist. This mechanism involves the drug competitively binding to beta1 receptors, which are highly expressed in myocardial tissue. This binding blocks the stimulating effects of endogenous catecholamines (e.g., norepinephrine and epinephrine), modifying initial molecular steps that precede downstream signaling. The physiological consequence is a direct reduction in the rate and force of heart contractions, resulting in decreased myocardial oxygen demand.


Modulation of Sympathetic Signaling Cascades

The blockade of cardiac beta1 receptors interrupts signaling sequences normally activated by sympathetic activity. This affects key pathways associated with systemic physiological responses, particularly those related to the suppression of renin release from the juxtaglomerular apparatus in the kidneys. By modulating these signaling cascades, Plenacor influences systems that govern systemic vascular resistance and cardiac function.

Dosage and Administration Information

How to Use Plenacor

Plenacor (Atenolol) usage is governed by specific administration principles, defining its route, dosage, and patient-specific adjustments. The medicine is primarily used as an oral tablet for continuous, long-term management of conditions like hypertension and angina. However, an intravenous (IV) form is utilized for initial, acute interventions in a hospital setting, such as following a myocardial infarction.

Official Dosing and Frequency Patterns

The standard oral dosage for adults typically begins with 25 mg or 50 mg taken once daily. For conditions like hypertension, the usual maintenance dose ranges from 50 mg to 100 mg once daily, while the dose for angina may be increased up to a maximum of 200 mg daily. Dosing is generally titrated (gradually adjusted) over time based on the response. The tablet should be swallowed whole, and some instructions indicate taking it before meals.

Population and Contextual Adjustments

Dose modifications are specified for certain populations. For patients with impaired renal function, the dose is typically reduced according to their creatinine clearance to prevent drug accumulation. For example, for severe impairment (CrCl <15 mL/min), the dose is often limited to 25 mg daily. Treatment in older adults may also be initiated at a lower starting dose.

Therapy cessation must adhere to a gradual reduction pattern, as abrupt discontinuation is not the standard procedure. Oral tablets in 50 mg and 100 mg strengths are scored, which allows them to be divided for precise dosing when necessary.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Plenacor

The research base for Plenacor, whose active ingredient is Atenolol, primarily consists of large-scale randomized controlled trials (RCTs) and systematic reviews that have explored its role in major heart and circulatory conditions. The following summary outlines the types of research that exist and the patterns observed in those studies, consistent with the broader evidence landscape.


Evidence for Use in Managing Chronic High Blood Pressure

Research on Plenacor's active ingredient in managing high blood pressure (hypertension) has been a significant focus of cardiovascular study for many years. Large RCTs have been used to compare its study against a placebo, against no treatment, and against other active drug arms. These studies included general adult populations, as well as those with established cardiovascular risk factors.

The research examined several outcomes related to systemic or functional imbalance, including changes in both the upper and lower blood pressure readings. Long-term studies monitored the rate of serious cardiovascular events, such as stroke and myocardial infarction. Studies reported measurements of reductions in blood pressure during the observed time period. When compared to no treatment, the research highlights changes measured during the study period that were associated with a lower occurrence of certain major cardiovascular events.

It is important to note that when modern systematic reviews compared the findings for this active ingredient against some of the newer antihypertensive drug classes, research has explored whether the reported patterns in preventing long-term outcomes like stroke and all-cause mortality were consistent. In this comparative context, the findings were mixed, and data for certain groups remain insufficient. The evidence provides context but not individual predictions, and research is ongoing in this area.


Evidence for Management of Chest Pain (Angina Pectoris)

The use of Plenacor's active ingredient in the context of chronic stable angina was evaluated through multiple RCTs, sometimes compared to other medications used for angina or to a placebo. These trials typically included adults with stable, effort-induced angina.

The studies focused on outcomes related to physical discomfort, specifically measuring the number of times a person experienced an angina episode and how often they required rescue medication, such as nitroglycerin. Researchers also applied studies examining patient-reported experiences related to their ability to tolerate physical activity or exercise before the onset of pain. Research highlights changes measured during the study period where fewer episodes of angina were reported and measurements of higher physical capacity were observed in the study populations.

The evidence for this indication primarily concentrates on short- to medium-term symptomatic expression and functional measures. Long-term data remain limited for specifically evaluating the prevention of major heart events in the angina population over many years when used as a single therapy.

Frequently Asked Questions (FAQ)

Common questions about Plenacor (FAQ)


Q: Is it normal to feel tired when starting Plenacor?

Yes, official product information lists fatigue, or general tiredness, as one of the most common side effects reported by people using this medicine. This information comes from reports collected during clinical studies. The full spectrum of documented effects is detailed in the official product information.


Q: Does Plenacor interact with common over-the-counter pain relievers?

Regulatory information indicates that certain over-the-counter pain relievers, specifically those known as Prostaglandin Synthetase Inhibiting Drugs (NSAIDs), may reduce the effect of Plenacor intended to lower blood pressure. Information consistency requires the healthcare professional to be aware of all medicines being used, including those purchased over the counter.


Q: Is Plenacor known to interact with caffeine?

While caffeine is not always explicitly listed in the formal interaction sections, the principle of how Plenacor works suggests that stimulants, including caffeine, could potentially counteract the medicine’s intended effects, such as slowing the heart rate. This is because Plenacor is a beta blocker designed to moderate the body's response to stress hormones.


Q: Are there any specific vitamins or supplements that interact with Plenacor?

Official documentation notes a possible interaction with certain supplements. Specifically, Multivitamin with Minerals has been documented to moderately reduce the body’s absorption of Plenacor. The potential for reduced absorption in official reports highlights the importance of discussing administration timing with a healthcare provider.


Q: Is Plenacor safe to use for teenagers?

Official labeling states that the safety and effectiveness of Plenacor have not been established for use in children and adolescents under the age of 18. Consequently, its use is not generally recommended in this younger population.


Q: Is Plenacor a blood thinner?

No, Plenacor is classified as a beta-adrenergic blocking agent, which is a type of medicine known as a beta blocker. Its mechanism is focused on reducing the heart's workload. It does not belong to the pharmacological class of medicines commonly referred to as blood thinners (anticoagulants or antiplatelet drugs).


Q: How is Plenacor eliminated from the body?

According to the official clinical pharmacology information, Plenacor is processed very little by the liver. Instead, the absorbed portion of the medicine is eliminated from the body primarily through excretion by the kidneys. This excretion mechanism is why dose modifications are mandated in official documents for individuals with reduced kidney function.


Q: What does 'contraindicated' mean in relation to Plenacor?

In medical and regulatory language, a medicine being 'contraindicated' means that its use is strictly prohibited for people who have certain pre-existing medical conditions. For Plenacor, this includes conditions like severe heart block or cardiogenic shock, where the risks of taking the medicine are considered too high.


Q: Are there any required tests before starting Plenacor?

Due to how the medicine is cleared from the body, dose adjustments are mandated for patients with reduced kidney function. Because of this, official instructions often require assessment of renal function, such as creatinine clearance, before a person starts using Plenacor.


Q: Is it possible to become dependent on Plenacor?

Official documentation emphasizes that therapy must not be stopped suddenly, but adherence to a gradual reduction pattern is officially required. Abrupt cessation carries an official risk, particularly for those with heart disease, that symptoms like angina may increase in frequency or severity, or that the cardiac state may deteriorate.


Q: Does Plenacor affect driving or operating machinery?

Official warnings advise caution regarding activities that require alertness, such as driving or operating hazardous machinery. This is because side effects like dizziness, lightheadedness, or fatigue may be experienced by some patients, as individuals need to establish how the medicine affects their alertness.


Q: What is the average time a patient takes Plenacor?

Plenacor is approved for the long-term management of chronic cardiovascular conditions, such as high blood pressure and angina pectoris. The long-term management designation indicates that its use is typically continuous.


Q: Why do some official sources refer to Plenacor by another name?

Official documents often refer to the medicine by its active ingredient, Atenolol. This is the non-proprietary or generic name for the drug, which is the chemical component that makes the medicine work. Plenacor is the specific brand name.


Q: Does Plenacor work instantly or does it build up over time?

The initial beta-blocking effect can be observed within one hour after taking an oral dose. However, the full therapeutic effects, particularly when used to lower high blood pressure, typically require continuous use and are usually fully established after one to two weeks.


Q: What is the typical duration of Plenacor's effect after one use?

Following a single oral dose, the primary effects of Plenacor, including its beta-blocking action and blood pressure lowering effect, are officially reported to persist for at least 24 hours. This duration supports its common once-daily dosing pattern.


Q: Are there different forms of Plenacor (e.g., tablet, capsule)?

According to official documentation, Plenacor is predominantly available as a solid oral tablet. Additionally, an intravenous (IV) form is officially approved for initial, acute interventions when rapid action is needed in a hospital setting.


Q: Is the research for Plenacor recent or older?

The active ingredient in Plenacor, Atenolol, has a long history of use. Its effectiveness is supported by large-scale randomized controlled trials that have been conducted over many years, establishing its role as a well-studied, foundational cardiovascular medicine.


Q: Can Plenacor be used alongside herbal remedies?

Herbal remedies and supplements are typically not evaluated in the same rigorous manner as prescription medicines, and there is often insufficient official information regarding their potential interactions. The use of herbal remedies typically requires professional consultation due to the lack of official interaction data.


Q: What is the difference between an 'adverse event' and a 'side effect' for Plenacor?

In regulatory safety documentation, a side effect is usually defined as an expected or known undesirable effect of the medicine, which may be mild or serious. An adverse event is a broader term for any undesirable experience associated with the use of a drug, regardless of whether the drug caused it.


Q: Does Plenacor change how the body processes sugar?

Official warnings state that Plenacor can intensify the effect of certain antidiabetic medicines. Furthermore, it may mask the physical warning signs, such as a fast heartbeat, associated with hypoglycemia (low blood sugar), which suggests it influences related physiological processes.


Q: Are the safety facts for Plenacor consistent across different countries?

Safety facts are compiled from a common global body of evidence and clinical trials. Major governmental agencies worldwide (such as the FDA, EMA, and TGA) use standardized medical language to document these facts, resulting in a highly consistent safety profile across different jurisdictions.


Q: How long does Plenacor stay in your system after the last use?

Official clinical pharmacology data indicates that the medicine has an elimination half-life of approximately 6 to 7 hours. This is the time it takes for the concentration of the medicine in the body to be reduced by half. The overall time for complete elimination is influenced by individual factors, especially kidney function.


Q: Is Plenacor the same kind of medicine as [similar generic drug name]?

Plenacor is classified as a beta1-selective adrenergic antagonist, which places it within the class of medicines known as beta blockers. This means it shares a general mechanism with other medicines in this class, but each specific product has its own unique chemical composition and properties.


Q: How quickly is Plenacor expected to start working?

The initial beta-blocking effect, which is measured by a reduction in exercise heart rate, is typically apparent within one hour after the oral administration of a single dose, according to clinical study data.


Q: Do studies show that Plenacor is effective for the long term?

Clinical trials for Plenacor's active ingredient have focused on its use for chronic conditions. These studies have shown that its continued use provides benefits in the long-term management of both high blood pressure (hypertension) and stable chest pain (angina pectoris).


Q: How does the research evidence for Plenacor compare to placebo?

Randomized controlled trials have compared Plenacor against an inactive placebo. The evidence indicates that the drug provides a significant reduction in blood pressure, and observed patterns in the research suggest a lower occurrence of certain serious cardiovascular events when compared to no treatment.


Q: Can Plenacor affect blood pressure readings?

Yes, Plenacor is officially indicated for the treatment of hypertension, which is high blood pressure. Clinical trials confirmed its effectiveness in lowering both systolic and diastolic blood pressure. Its primary action is to reduce the heart's workload, which results in this lowering effect.


Q: Is it possible to be allergic to Plenacor?

Official labeling states that Plenacor is contraindicated, or strictly prohibited, in any patient with a known history of hypersensitivity or allergic reaction to the active ingredient (Atenolol) or any of the inactive components of the product.


Q: Does Plenacor interact with any common foods?

Official documentation specifically mentions that the consumption of large amounts of orange juice may decrease the effectiveness of Plenacor by reducing the amount of medicine the body absorbs. No other common foods are highlighted in this specific context.

How should Plenacor be stored and disposed of?

Storage

To maintain its effectiveness, Plenacor (Atenolol) tablets should be stored at room temperature, typically between 68 F and 77 F (20 C and 25 C). Keep the medication in its original container, sealed, and away from excess moisture, heat, and direct light. Do not store Plenacor in a bathroom, where humidity can be high. As with all medications, ensure it is kept safely out of the sight and reach of children and pets.

Disposal

To dispose of unused or expired Plenacor, follow guidelines for safe medicine disposal to protect the environment and prevent accidental ingestion. The best method is to utilize a community drug take-back program or an authorized mail-back envelope. If a take-back option is unavailable, you can dispose of the medicine in your household trash after mixing the tablets with an unappealing substance, such as used coffee grounds or cat litter, and sealing the mixture in a container or plastic bag. Do not crush the tablets. Always remove or scratch out all personal information on the prescription label before discarding the packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Plenacor found in:

A-Z Index: